Key Accounts Director (Chicago ​/ Remote

About Summit

Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit’s core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people.

Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence.

Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit’s core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people.

Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence.

Summit’s Team Is Inspired To Touch And Help Change Lives Through Summit’s Clinical Studies In The Field Of Oncology. Summit Has Multiple Global Phase 3 Clinical Studies, Including

• HARMONi:
  Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI.
• HARMONi-3:
  Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC.
• HARMONi-7:
  Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC.

• HARMONi-GI3:
  Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy.

Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA). Summit is headquartered in Miami, Florida, and has additional offices in California, New Jersey, the UK, and Ireland.

The Key Account Director (KAD) is responsible for establishing and maintaining strategic relationships that enable optimal market access for Summit Therapeutics’ innovative oncology medicines. This includes engagement across IDNs, Academic Centers, regional health systems, and select parent accounts of community provider networks. These are regionally aligned positions, with each Key Account Director responsible for a defined geography and corresponding accounts.

The Key Account Director will develop and execute strategic account plans designed to support rapid product adoption through clinical pathway and treatment protocol inclusion, while representing Summit Therapeutics with key executive decision-makers across key oncology accounts (IDNs, Academic Centers, regional health systems, and community network parent organizations). This Market Access role also coordinates cross-functional collaboration across Commercial, Medical Affairs, Legal, and Marketing, to ensure alignment and successful integration of Summit’s therapies within provider-driven pathways.

• Translate national brand and access strategies into actionable engagement plans across IDNs, Academic Centers, regional health systems, and select parent accounts of community provider networks.
• Lead account strategy and execution focused on accelerating clinical pathway and treatment protocol inclusion post-launch, in close partnership with Medical Affairs, Legal, Marketing, and Commercial functions.
• Establish and maintain business-to-business…